Noelle K. LoConte, MD Print Friendly PageFaculty, University of Wisconsin School of Medicine and Public Health
Dr. LoConte is an assistant professor of medicine at the University of Wisconsin. She completed medical school at the University of Illinois at Chicago, then did her internship in internal medicine at the UW. Dr. LoConte completed her internal medicine residency at Oregon Health Sciences University in Portland. She has also completed fellowship training in both medical oncology as well as geriatrics, and is one of the few physicians practicing in the Midwest with such dual training. She joined the faculty of the UW Carbone Cancer Center in the summer of 2006. She is the recipient of the American Society of Clinical Oncology Young Investigator Award for 2006. Dr. LoConte's clinical interests are in gastrointestinal cancers, including liver and pancreas cancers, as well as cancer of any type in the older adult.
UW Health Clinics
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
UW School of Medicine and Public Health
|Department of Medicine|
Professional Certifications and Education
University of Wisconsin Hospital and Clinics, Madison, WI
Oregon Health Sciences University, Portland
University of Wisconsin Hospital and Clinics, Madison, WI
University of Illinois, Chicago, 2000
Our doctors provide a wide range of services. The following list represents some, but not all, of the procedures offered by this physician.
Dr. LoConte's research interests are in predictors of chemotherapy toxicity, as well as trials of chemotherapy in older adults and patients with gastrointestinal cancers.
Neuman HB Weiss JM Schrag D Ronk K Havlena J Loconte NK Smith MA Greenberg CC .
Patient demographic and tumor characteristics influencing oncologist follow-up frequency in older breast cancer survivors. Ann Surg Oncol. 2013 Dec;20(13):4128-36
[PubMed ID: 23943027]
LoConte NK Weeth-Feinstein L Conlon A Scott S .
Engaging health systems to increase colorectal cancer screening: community-clinical outreach in underserved areas of Wisconsin. Prev Chronic Dis. 2013 Nov 21;10:E192
[PubMed ID: 24262024]
Caretta-Weyer H Greenberg CG Wilke LG Weiss J Loconte NK Decker M Steffens NM Smith MA Neuman HB .
Impact of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial on Clinical Management of the Axilla in Older Breast Cancer Patients: A SEER-Medicare Analysis. Ann Surg Oncol. 2013 Aug 20;
[PubMed ID: 23959051]
LoConte NK Holen KD Schelman WR Mulkerin DL Deming DA Hernan HR Traynor AM Goggins T Groteluschen D Oettel K Robinson E Lubner SJ .
A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. Invest New Drugs. 2013 Aug;31(4):943-8
[PubMed ID: 23263993]
Neuman HB Weiss JM Leverson G O'Connor ES Greenblatt DY Loconte NK Greenberg CC Smith MA .
Predictors of short-term postoperative survival after elective colectomy in colon cancer patients ≥ 80 years of age. Ann Surg Oncol. 2013 May;20(5):1427-35
[PubMed ID: 23292483]
Cetnar J Wilding G McNeel D LoConte NK McFarland TA Eickhoff J Liu G .
A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer. Urol Oncol. 2013 May;31(4):436-41
[PubMed ID: 21481618]
Neuman HB O'Connor ES Weiss J Loconte NK Greenblatt DY Greenberg CC Smith MA .
Surgical treatment of colon cancer in patients aged 80 years and older : analysis of 31,574 patients in the SEER-Medicare database. Cancer. 2013 Feb 1;119(3):639-47
[PubMed ID: 22893570]
Weiss JM Pfau PR O'Connor ES King J LoConte N Kennedy G Smith MA .
Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results--Medicare data. J Clin Oncol. 2011 Nov 20;29(33):4401-9
[PubMed ID: 21969498]
O'Connor ES Greenblatt DY LoConte NK Gangnon RE Liou JI Heise CP Smith MA .
Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011 Sep 1;29(25):3381-8
[PubMed ID: 21788561]
O'Mahar SE Campbell TC Hoang T Seo S Kim K Larson MM Marcotte SM LoConte NK Traynor AM .
Phase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancer. J Thorac Oncol. 2011 May;6(5):951-3
[PubMed ID: 21623267]
Kennedy GD Rajamanickam V O'connor ES Loconte NK Foley EF Leverson G Heise CP .
Optimizing surgical care of colon cancer in the older adult population. Ann Surg. 2011 Mar;253(3):508-14
[PubMed ID: 21169811]
Dennie TW Fleming RA Bowen CJ Dar MM Alberti D Oliver K Loconte N Mulkerin D Holen KD .
A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors. Clin Colorectal Cancer. 2011 Mar 1;10(1):57-62
[PubMed ID: 21609937]
Lepeak L Tevaarwerk A Jones N Williamson A Cetnar J LoConte N .
Persistence in breast cancer disparities between African Americans and whites in Wisconsin. WMJ. 2011 Feb;110(1):21-5
[PubMed ID: 21473509]
Loconte NK Williamson A Gayle A Weiss J Leal T Cetnar J Mohammed T Tevaarwerk A Jones N .
Increasing Disparity in Colorectal Cancer Incidence and Mortality Among African Americans and Whites: A State's Experience. J Gastrointest Oncol. 2011;2(2):85-92
[PubMed ID: 21712962]
Mohammed TA Holen KD Jaskula-Sztul R Mulkerin D Lubner SJ Schelman WR Eickhoff J Chen H Loconte NK .
A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. Oncologist. 2011;16(6):835-43
[PubMed ID: 21632454]
Lubner SJ Kunnimalaiyaan M Holen KD Ning L Ndiaye M Loconte NK Mulkerin DL Schelman WR Chen H .
A preclinical and clinical study of lithium in low-grade neuroendocrine tumors. Oncologist. 2011;16(4):452-7
[PubMed ID: 21393344]
Lubner SJ Mahoney MR Kolesar JL Loconte NK Kim GP Pitot HC Philip PA Picus J Yong WP Horvath L Van Hazel G Erlichman CE Holen KD .
Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol. 2010 Jul 20;28(21):3491-7
[PubMed ID: 20530271]
Lubner SJ Loconte NK Holen KD Schelman W Thomas JP Jumonville A Eickhoff JC Seo S Mulkerin DL .
A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2010 Jul;9(3):157-61
[PubMed ID: 20643620]
Greenblatt DY Weber SM O'Connor ES LoConte NK Liou JI Smith MA .
Readmission after colectomy for cancer predicts one-year mortality. Ann Surg. 2010 Apr;251(4):659-69
[PubMed ID: 20224370]
LoConte NK Smith M Alberti D Bozeman J Cleary JF Setala AN Wodtke G Wilding G Holen KD .
Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy. Cancer Chemother Pharmacol. 2010 Mar;65(4):775-80
[PubMed ID: 19649630]